-
Reducing duration of antibiotic therapy without a diminution in efficacy decreases cost, side effects, antibiotic related diarrhoea, and bacterial resistance. A letter summarizes various obtained results.
Critical Care (Infectious Diseases) - Tue, 10 January 2012
http://ccforum.com
-
Treating latent tuberculosis (TB) infection to prevent progression to TB disease is a cornerstone of the U.S. strategy for TB elimination. People with latent tuberculosis (TB) infection now have another option when it comes to treatment. A new regimen for the treatment of latent TB infection, called the 12-dose regimen, reduces the number of doses and shortens the duration of treatment.
Centers for Disease Control and Prevention (CDC) (Infectious Diseases) - Tue, 13 December 2011
http://www.cdc.gov/
-
The Report on the global HIV/AIDS response shows that increased access to HIV services resulted in a 15% reduction of new infections over the past decade and a 22% decline in AIDS-related deaths in the last five years. While there is still much to be done, 2011 was a game changing year, in terms of current progress and innovations creating hope for substantial future advances.
World Health Organization (Infectious Diseases) - Tue, 6 December 2011
http://www.who.int
-
A new article from the National Institutes of Health (NIH), in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine, highlights that, although it may not be possible to create a vaccine that completely prevents EBV infection, the authors note, clinical observations and results from clinical trials of an experimental EBV vaccine suggest that it may be possible to create an EBV vaccine capable of preventing the diseases that sometimes follow EBV infection.
National Institute of Allergy and Infectious Diseases (Infectious Diseases) - Mon, 7 November 2011
http://www.niaid.nih.gov/
-
Septicemia, an illness caused by blood infections with bacteria such as E. coli and methicillin-resistant Staphylococcus aureus, was the single most expensive condition treated in U.S. hospitals at nearly $15.4 billion in 2009, according to the latest News and Numbers from the Agency for Healthcare Research and Quality (AHRQ). Data include cases of septicemia acquired within the community and during hospital stays.
AHRQ - Agency for Healthcare Research and Quality (Infectious Diseases) - Wed, 2 November 2011
http://www.ahrq.gov
-
The 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) brings together a variety of health care professionals involved in research, patient care, public health, disease prevention and education relating to infectious diseases.
National Institute of Allergy and Infectious Diseases (Infectious Diseases) - Tue, 25 October 2011
http://www.niaid.nih.gov/
-
In a video, Sandra Fryhofer, Clinical Associate Professor of Medicine, Emory University School of Medicine, describes the latest evidence on the benefits of the human papillomavirus vaccine in men, especially in preventing anal cancers.
Medscape (Infectious Diseases) - Tue, 11 October 2011
http://www.medscape.com
-
The study reports 115 influenza–associated deaths of people younger than 18, from September 2010 through August 2011 and highlights the importance of both annual vaccination and rapid antiviral treatment.
Centers for Disease Control and Prevention (CDC) (Infectious Diseases) - Tue, 20 September 2011
http://www.cdc.gov/
-
Targeted action is needed to prevent the spread of tuberculosis (TB) and ensure treatment success among patients who have difficulty recognising symptoms, accessing health services and taking medication. The patients who are hardest to reach through traditional hospital based TB services include people with drug or alcohol addiction, homeless people, prisoners and some migrant communities.
National Institute for Health and Clinical Excellence (Infectious Diseases) - Mon, 12 September 2011
http://www.nice.org.uk
-
Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up, according to researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues.
National Institutes of Health (Infectious Diseases) - Mon, 12 September 2011
http://www.nih.gov